Inspiremd reports second quarter 2023 financial results and provides business update

- completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - completed enrollment in the c-guardians us ide trial; on track to announce primary and secondary endpoints and, if successful, submit pma application in h2 2024 – - generated q2 2023 cguard eps revenue of $1.6 million, an increase of nearly 10% over q2 2022 – -- management to host investor conference call today, august 8, at 8:30am et -- tel aviv, israel, and miami, aug. 08, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for treatment of carotid artery disease and prevention of stroke today announced financial and operating results for the second quarter ended june 30, 2023. second quarter 2023 and recent developments: successfully completed a transformational private placement of common shares, prepaid warrants and warrants for up to $113.6 million in gross proceeds, including $42.2 million upfront and additional proceeds of up to $71.4 million upon exercise of milestone-driven warrants.
NSPR Ratings Summary
NSPR Quant Ranking